A liver-cancer target and molecule identified with Pharma.AI
Pharma.AI combined PandaOmics, Chemistry42 and an AlphaFold-predicted structure to identify a hepatocellular-carcinoma target and produce a hit molecule within 30 days of target selection, synthesizing seven compounds. A second round produced a more potent hit; an early Chemical Science study, with no clinical efficacy demonstrated.
Technology: Pharma.AI, PandaOmics, Chemistry42 and AlphaFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Selected compounds were synthesized and tested in biological assays: the first hit bound CDK20 (Kd about 9.2 µM) and a second AI-driven round gave a more potent compound with greater antiproliferative activity in liver cancer cells; the abstract describes no in vivo testing.
- Still unknown: The abstract notes AlphaFold predictions have varying confidence, the first hit came from only 7 synthesized compounds, and potency values vary widely; no clinical efficacy is demonstrated.
- AI role: Pharma.AI platforms (PandaOmics, Chemistry42) used AlphaFold-predicted structures to select a liver-cancer target and generate candidate molecules.
Evidence sources: https://www.utoronto.ca/news/researchers-use-ai-powered-database-design-potential-cancer-drug-30-days · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1039/D2SC05709C&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 403 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.